Pr Jacques MorelRhumatologue à Montpellier

Hospitalo-universitaire

Appeler· 04 67 33 67 33 Rechercher sur Doctolib

Egora · 2026Rhumatismes inflammatoires : l’Eular appelle à vacciner au plus tôt - EgoraLire l'article ↗

Photo : Wolfgang Staudt from Saarbruecken, Germany, CC BY 2.0, Wikimedia Commons

Dans les médias

Egora
lopinion.com
Fédération des maisons médicales

Vous êtes Pr Jacques Morel ? Présentation, expertises, actes, site du cabinet : faites de cette fiche la page de votre cabinet.

Configurer votre fiche gratuitement →

Pr Jacques Morel est rhumatologue à Montpellier (34295). Il consulte notamment à CABINET PRIVE DU DR JACQUES MOREL, HOPITAL LAPEYRONIE, IMMUNO-RHUMATOLOGIE — 371 AVENUE DU DOYEN GASTON GIRAUD, 34295 Montpellier (2 lieux au total). Il accepte la carte Vitale.

Enregistrer le contact

publications: 50publications
citations: 12 137citations
vidéo: 1vidéo
articles de presse: 2articles de presse

Consulter

Lieux de consultation

CABINET PRIVE DU DR JACQUES MOREL

Pr Jacques Morel, c'est vous ?

Faites de cette fiche la page de votre cabinet.

Votre présentationQuelques lignes sur votre pratique, affichées en tête de page.
Vos domaines d'expertiseLes pathologies que vous suivez, à la place des domaines déduits.
Vos actesÉchographie, infiltrations, viscosupplémentation, PRP, téléexpertise.
Vos liensSite du cabinet, LinkedIn, secteur de conventionnement corrigé.

Configurer votre fiche gratuitementGratuit · réservé au praticien

En bref

Questions fréquentes sur Pr Jacques Morel

Où consulte Pr Jacques Morel ?

Pr Jacques Morel exerce dans 2 lieux : CABINET PRIVE DU DR JACQUES MOREL, HOPITAL LAPEYRONIE, IMMUNO-RHUMATOLOGIE — 371 AVENUE DU DOYEN GASTON GIRAUD, 34295 Montpellier et HOPITAL LAPEYRONIE CHU MONTPELLIER, 371 Avenue DU DOYEN GASTON GIRAUD, 34295 Montpellier. Adresses issues de l'Annuaire Santé (ANS).

Comment prendre rendez-vous avec Pr Jacques Morel ?

Par téléphone au 04 67 33 67 33 (numéro publié à l'Annuaire Santé). Un lien de recherche Doctolib est proposé sur cette page : si le praticien y est inscrit, son profil figure normalement parmi les résultats.

Pr Jacques Morel accepte-t-il la carte Vitale ?

Oui. Source : Assurance Maladie.

D'où viennent les informations de cette page ?

Identité, diplômes et lieux d'exercice : Annuaire Santé (ANS, licence ouverte). Conventionnement et carte Vitale : Assurance Maladie. Publications : bases scientifiques publiques (PubMed, HAL, OpenAlex), affichées seulement si le nom du praticien figure parmi les auteurs. Le praticien peut corriger sa fiche ou en demander le retrait à tout moment ; en cas d'homonymie, signalez-le.

Polyarthrite rhumatoïde · 18

2026Joint bone spinePubMed

Weight change and longitudinal disease activity in rheumatoid arthritis: A real-world cohort study

2025The Lancet. RheumatologyPubMed

Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial

2025Joint bone spinePubMed

Risk of cancer in patients with rheumatoid arthritis under tocilizumab: Data from the French national registry REGATE

2025ACR open rheumatologyPubMed

Polypharmacy in Early Rheumatoid Arthritis: Impact on Treatment Response and Adverse Event Risk in a multicenter French prospective cohort study

2025BMJ openPubMed

Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial

2025ACR open rheumatologyPubMed

Analysis of the Impact of Tofacitinib Treatment on Weight and Body Mass Index in Patients With Rheumatoid Arthritis

2025Rheumatology (Oxford, England)PubMed

Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort

2025Annals of the rheumatic diseasesPubMed

Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial

2024Clinical and experimental rheumatologyPubMed

Comparison of SARS-COV-2 humoral response between rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients and controls in two unvaccinated cohorts

2024RMD openPubMed

Persistence of power Doppler ultrasonography-detected synovitis over 1 year of follow-up predicts poor prognosis in rheumatoid arthritis in clinical remission: the SONORE prospective longitudinal study

2024Arthritis & rheumatology (Hoboken, N.J.)PubMed

Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission

2023Arthritis care & researchPubMed

Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis

2022Rheumatology (Oxford, England)PubMed

Rheumatoid arthritis is associated with increased gut permeability and bacterial translocation which are reversed by inflammation control

2022Rheumatology (Oxford, England)PubMed

Rheumatoid arthritis is associated with increased gut permeability and bacterial translocation which are reversed by inflammation control

2022Rheumatology (Oxford, England)PubMed

CXCR5/CXCL13 pathway, a key driver for migration of regulatory B10 cells, is defective in patients with rheumatoid arthritis

2022Joint bone spinePubMed

Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry

2022Rheumatology (Oxford, England)PubMed

Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept

2021Rheumatology (Oxford, England)PubMed

Cut-off value to identify a flare using the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire: analysis of the TOSCA study

Sjögren · 11

2025Arthritis & rheumatology (Hoboken, N.J.)PubMed

Distinct Pathophysiologic Pathways Support Stratification of Sjögren's Disease Based on Symptoms, Clinical, and Routine Biological Data

2025Rheumatology (Oxford, England)PubMed

Are ultrasound salivary parenchymal lesions more severe in primary Sjögren patients with a longer disease duration? A cross-sectional study

2024The Lancet. RheumatologyPubMed

Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts

2023Cancer immunology, immunotherapy : CIIPubMed

Chronological interplay, clinical features, and treatments among patients with cancer and primary Sjögren's syndrome

Transversal · 10

2026Joint bone spinePubMed

Efficacy and Tolerance of a Combination of Targeted Therapies Indicated for Asthma and Chronic Inflammatory Rheumatism

2026Rheumatology (Oxford, England)PubMed

Stability and prognostic value of B-cell markers in primary SS: results from the French ASSESS cohort

2026International journal of infectious diseases : IJID : official publication of the International Society for Infectious DiseasesPubMed

Accuracy of VIDAS(Ⓡ) TB-IGRA in TB patients and individuals with different thresholds of exposure

2025RMD openPubMed

Adaptive immune responses to SARS-CoV-2 in DMARD-treated patients with chronic inflammatory rheumatisms

Biothérapies non-anti-TNF · 6

2025Joint bone spinePubMed

Risk of cancer in patients with rheumatoid arthritis under tocilizumab: Data from the French national registry REGATE

2025BMJ openPubMed

Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial

2024Rheumatology (Oxford, England)PubMed

Can efficacy and safety data from clinical trials of rituximab in RA be extrapolated? Insights from 1984 patients from the AIR-PR Registry

2024Arthritis & rheumatology (Hoboken, N.J.)PubMed

Rhumatisme psoriasique · 3

2024Clinical and experimental rheumatologyPubMed

Comparison of SARS-COV-2 humoral response between rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients and controls in two unvaccinated cohorts

2024RMD openPubMed

Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study

2022Rheumatology (Oxford, England)PubMed

Toward a holistic management of skin and joint disorders in PsA patients

Anti-TNF · 2

2025Rheumatology (Oxford, England)PubMed

Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort

2022Joint bone spinePubMed

Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry

csDMARDs · 2

2026Rheumatology (Oxford, England)PubMed

One-month delay in MTX initiation on RA outcomes: 1-year ancillary analysis of the VACIMRA trial

2025The Lancet. RheumatologyPubMed

Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial

Maladie de Horton · 2

2025La Revue de medecine internePubMed

Use of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)

2025La Revue de medecine internePubMed

French protocol for the diagnosis and management of giant cell arteritis

Vascularites · 2

2025La Revue de medecine internePubMed

Use of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)

2022Autoimmunity reviewsPubMed

Sjögren syndrome overlapping with ANCA-associated vasculitis: Four additional cases and systematic literature review

Comorbidités · 1

2024RMD openPubMed

Systematic screening for multimorbidities in patients with inflammatory rheumatic diseases enhanced preventive medication use and reduced hospitalisations: an exposed-non-exposed study

Échographie · 1

2024RMD openPubMed

JAK inhibiteurs · 1

2025ACR open rheumatologyPubMed

Analysis of the Impact of Tofacitinib Treatment on Weight and Body Mass Index in Patients With Rheumatoid Arthritis

Polymyalgia rheumatica · 1

2024Joint bone spinePubMed

Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumatica

Recommandations · 1

2023Annals of the rheumatic diseasesPubMed

2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases

Sclérodermie · 1

2025Respiratory medicine and researchPubMed

Phenotypes and prognosis of systemic sclerosis: A cluster analysis

Spondyloarthrite · 1

2024Clinical and experimental rheumatologyPubMed

Comparison of SARS-COV-2 humoral response between rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients and controls in two unvaccinated cohorts

Pr Jacques MorelRhumatologue à Montpellier

Lieux de consultation

Préparer votre rendez-vous

Conventionnement et remboursement

Expertise et points clés

Parcours et diplômes (9)

Travaux scientifiques (60)

Vidéos et presse (3)

Questions fréquentes sur Pr Jacques Morel

Où consulte Pr Jacques Morel ?

Comment prendre rendez-vous avec Pr Jacques Morel ?

Pr Jacques Morel accepte-t-il la carte Vitale ?

D'où viennent les informations de cette page ?

Rhumatologues à Montpellier et alentours